Fusion Antibodies Plc (LSE:FAB) was quoted at 10.56 GBX on 26 August 2026, a decline of 6.18% on the session. The movement placed the company among the softer performers across the London market during the day's trading.
Oxford Nanopore Technologies plc (LSE:ONT) was quoted at 178.70 GBX on 26 August 2026, a decline of 2.35% on the session. The movement placed the company among the softer performers across the London market during the day's trading.
ProBiotix Health Plc (LSE:PBX) remained on investors’ radar after a single trade lifted the shares by approximately 16.02% during the previous session.
Sareum Holdings Plc (LSE:SAR), the AIM-quoted biotechnology company developing next-generation kinase inhibitors, extended its recent rally on 26 August 2026. After closing at 37p in the previous session, the shares traded at approximately 38p, representing a further gain of around 2.70%.
The immediate catalyst on the day was modest in isolation: a 2.87% advance to 143.5p, valuing the company at about £118m. That places Diaceutics firmly in small-cap territory, whereLiquidityis thin and daily moves can be exaggerated by relatively small volumes. There was no fresh …
Coiled Therapeutics Plc has become an increasingly watched small-cap healthcare stock because itsInvestmentcase is now centred around clinical development rather than established commercial revenues.
MedPal AI PLC has become one of the more closely watched smaller UK healthcare technology shares because it sits at the intersection of several powerfulInvestmentthemes: artificial intelligence, digital healthcare, personalised wellness, online pharmacy services and the rapidly expanding weight-management market.
Ondine Biomedical has become one of the more closely watched small-cap healthcare stocks because its technology addresses several major healthcare challenges simultaneously.
AOTI shares rose by 2.52% as the market continued to assess the significance of the company’s recent operating update and the proposed Medicare coverage pathway for topical oxygen therapy. The update indicated resilient underlying demand, a recovery in the Veterans AdministrationBusinessand improving working-capital conditions.
The share-price increase appears to reflect continued investor appreciation of Diaceutics’ improving commercial and financial profile. Its latest trading update reported strong expansion in annual recurring revenue, underlying sales growth and a substantial contracted order book. These indicators provide greater visibility over future performance …